Introduction The visceral leishmaniosis (VL), or Calazar, is a chronic severe systemic disease, potentially fatal to humans. Currently, VL is the prototype of a specific immune dysfunction resulting from parasitism of leishmania donovani in macrophages, producing a broad spectrum of clinical and immunological reversible only with specific treatment. Serum Analysis from infected adult patients d...

availability of a variety of lipids and to accommodate different types of antigens/immunomodulators [2,6]. While liposomes have initially reached the market as drug carriers, their potential as potent vaccine adjuvants has been demonstrated against several diseases such as HIV [7] tuberculosis [8], malaria [9] and leishmaniosis [10] indicating that liposomal systems have promising future as vac...

background: we aimed to assess the impact of health workers’ training program on preventive behaviors of leishmaniosis based on basnef (belief, attitude, subjective norm, and enabling factors) model in the families under the coverage of health centers. methods: the study was done in rural health centers of marvdasht city, fars province, iran in 2011. health workers completed a specific question...

A case is reported of a 19-year-old woman, at week 24 of gestation, with visceral leishmaniosis. She was treated with meglumine antimoniate at a dose of 850 mg/day for 20 days. There occurred premature birth on day five of treatment and the neonate died one day after birth. Considering the importance of protozoiasis in our population and the rarity of the association with pregnancy, we resolved...

Clinical manifestations of leishmaniasis are diverse and related to the infecting species, its relationship with the environment and the host immune response. A case of late Andean cutaneous leishmaniasis with extensive manifestation is presented. The case was confirmed through microbiological and immunological studies; identification was performed by cytochrome b gene sequencing and the specie...